FibroGen Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 39,636 shares of the company’s stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $44.20, for a total value of $1,751,911.20. Following the transaction, the chief executive officer now owns 2,449,106 shares of the company’s stock, valued at $108,250,485.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of NASDAQ FGEN opened at $44.31 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.16 and a quick ratio of 6.16. The firm has a market capitalization of $3.82 billion, a P/E ratio of -43.02 and a beta of 1.75. FibroGen Inc has a one year low of $33.51 and a one year high of $68.55.
FibroGen (NASDAQ:FGEN) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.15. The business had revenue of $23.90 million during the quarter, compared to analyst estimates of $20.44 million. FibroGen had a negative return on equity of 17.71% and a negative net margin of 44.14%. FibroGen’s revenue was down 25.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.50) earnings per share. Equities analysts anticipate that FibroGen Inc will post -0.87 EPS for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of FGEN. Vanguard Group Inc raised its stake in shares of FibroGen by 1.8% in the third quarter. Vanguard Group Inc now owns 6,921,874 shares of the biopharmaceutical company’s stock valued at $420,503,000 after purchasing an additional 125,186 shares in the last quarter. Bank of Montreal Can raised its stake in shares of FibroGen by 177.3% in the fourth quarter. Bank of Montreal Can now owns 1,722 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 1,101 shares in the last quarter. Rhumbline Advisers raised its stake in shares of FibroGen by 55.4% in the fourth quarter. Rhumbline Advisers now owns 111,700 shares of the biopharmaceutical company’s stock valued at $5,169,000 after purchasing an additional 39,812 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of FibroGen in the fourth quarter valued at $281,000. Finally, Canada Pension Plan Investment Board acquired a new position in shares of FibroGen in the fourth quarter valued at $2,133,000. Institutional investors and hedge funds own 66.27% of the company’s stock.
FibroGen Company Profile
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Featured Article: What is the Federal Reserve?
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.